Health Care·Biotechnology·$5.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | +29.71% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.22 | N/A | +29.71% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the company's progress in the quarter. They emphasized a commitment to advancing their drug pipeline.
We are pleased with our progress despite the challenges.
Our focus remains on advancing our pipeline.
Xenon Pharmaceutical reported a narrower loss than expected, which is a positive sign for investors. However, the stock fell by nearly 3% after the earnings report, indicating some investor caution. The lack of revenue figures and forward guidance may have contributed to the stock's decline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DANAOS CORP
May 18, 2020